Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 962

1.

LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade.

Sheng W, LaFleur MW, Nguyen TH, Chen S, Chakravarthy A, Conway JR, Li Y, Chen H, Yang H, Hsu PH, Van Allen EM, Freeman GJ, De Carvalho DD, He HH, Sharpe AH, Shi Y.

Cell. 2018 Jun 18. pii: S0092-8674(18)30715-3. doi: 10.1016/j.cell.2018.05.052. [Epub ahead of print]

PMID:
29937226
2.

Immune Checkpoint Blockade Restores HIV-Specific CD4 T Cell Help for NK Cells.

Porichis F, Hart MG, Massa A, Everett HL, Morou A, Richard J, Brassard N, Veillette M, Hassan M, Ly NL, Routy JP, Freeman GJ, Dubé M, Finzi A, Kaufmann DE.

J Immunol. 2018 Jun 22. pii: ji1701551. doi: 10.4049/jimmunol.1701551. [Epub ahead of print]

PMID:
29934472
3.

TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas.

Hamada T, Soong TR, Masugi Y, Kosumi K, Nowak JA, da Silva A, Mu XJ, Twombly TS, Koh H, Yang J, Song M, Liu L, Gu M, Shi Y, Nosho K, Morikawa T, Inamura K, Shukla SA, Wu CJ, Garraway LA, Zhang X, Wu K, Meyerhardt JA, Chan AT, Glickman JN, Rodig SJ, Freeman GJ, Fuchs CS, Nishihara R, Giannakis M, Ogino S.

Oncoimmunology. 2018 Mar 19;7(7):e1442999. doi: 10.1080/2162402X.2018.1442999. eCollection 2018.

PMID:
29900052
4.

PD-L1 binds to B7-1 only in cis on the same cell surface.

Chaudhri A, Xiao Y, Klee AN, Wang X, Zhu B, Freeman GJ.

Cancer Immunol Res. 2018 Jun 5. pii: canimm.0316.2017. doi: 10.1158/2326-6066.CIR-17-0316. [Epub ahead of print]

PMID:
29871885
5.

TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.

Liu HJ, Lizotte PH, Du H, Speranza MC, Lam HC, Vaughan S, Alesi N, Wong KK, Freeman GJ, Sharpe AH, Henske EP.

JCI Insight. 2018 Apr 19;3(8). pii: 98674. doi: 10.1172/jci.insight.98674. [Epub ahead of print]

6.

Role of PD-1 during effector CD8 T cell differentiation.

Ahn E, Araki K, Hashimoto M, Li W, Riley JL, Cheung J, Sharpe AH, Freeman GJ, Irving BA, Ahmed R.

Proc Natl Acad Sci U S A. 2018 May 1;115(18):4749-4754. doi: 10.1073/pnas.1718217115. Epub 2018 Apr 13.

PMID:
29654146
7.

2-Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety.

Dow RL, Ammirati M, Bagley SW, Bhattacharya SK, Buckbinder L, Cortes C, El-Kattan AF, Ford K, Freeman GB, Guimarães CRW, Liu S, Niosi M, Skoura A, Tess D.

J Med Chem. 2018 Apr 12;61(7):3114-3125. doi: 10.1021/acs.jmedchem.8b00152. Epub 2018 Apr 3.

PMID:
29570292
8.

Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles.

Ricklefs FL, Alayo Q, Krenzlin H, Mahmoud AB, Speranza MC, Nakashima H, Hayes JL, Lee K, Balaj L, Passaro C, Rooj AK, Krasemann S, Carter BS, Chen CC, Steed T, Treiber J, Rodig S, Yang K, Nakano I, Lee H, Weissleder R, Breakefield XO, Godlewski J, Westphal M, Lamszus K, Freeman GJ, Bronisz A, Lawler SE, Chiocca EA.

Sci Adv. 2018 Mar 7;4(3):eaar2766. doi: 10.1126/sciadv.aar2766. eCollection 2018 Mar.

9.

Dendritic Cell PD-L1 Limits Autoimmunity and Follicular T Cell Differentiation and Function.

Sage PT, Schildberg FA, Sobel RA, Kuchroo VK, Freeman GJ, Sharpe AH.

J Immunol. 2018 Apr 15;200(8):2592-2602. doi: 10.4049/jimmunol.1701231. Epub 2018 Mar 12.

PMID:
29531164
10.

RGMb protects against acute kidney injury by inhibiting tubular cell necroptosis via an MLKL-dependent mechanism.

Liu W, Chen B, Wang Y, Meng C, Huang H, Huang XR, Qin J, Mulay SR, Anders HJ, Qiu A, Yang B, Freeman GJ, Lu HJ, Lin HY, Zheng ZH, Lan HY, Huang Y, Xia Y.

Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1475-E1484. doi: 10.1073/pnas.1716959115. Epub 2018 Jan 30.

PMID:
29382757
11.

Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells.

Nakashima H, Alayo QA, Penaloza-MacMaster P, Freeman GJ, Kuchroo VK, Reardon DA, Fernandez S, Caligiuri M, Chiocca EA.

Sci Rep. 2018 Jan 9;8(1):208. doi: 10.1038/s41598-017-18540-2.

12.

T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity.

Schmid D, Park CG, Hartl CA, Subedi N, Cartwright AN, Puerto RB, Zheng Y, Maiarana J, Freeman GJ, Wucherpfennig KW, Irvine DJ, Goldberg MS.

Nat Commun. 2017 Nov 23;8(1):1747. doi: 10.1038/s41467-017-01830-8.

13.

Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.

Zhang J, Bu X, Wang H, Zhu Y, Geng Y, Nihira NT, Tan Y, Ci Y, Wu F, Dai X, Guo J, Huang YH, Fan C, Ren S, Sun Y, Freeman GJ, Sicinski P, Wei W.

Nature. 2018 Jan 4;553(7686):91-95. doi: 10.1038/nature25015. Epub 2017 Nov 16.

14.

CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation.

Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, Chhabra S, Huang W, Liu H, Aref AR, Ivanova E, Paweletz CP, Bowden M, Zhou CW, Herter-Sprie GS, Sorrentino JA, Bisi JE, Lizotte PH, Merlino AA, Quinn MM, Bufe LE, Yang A, Zhang Y, Zhang H, Gao P, Chen T, Cavanaugh ME, Rode AJ, Haines E, Roberts PJ, Strum JC, Richards WG, Lorch JH, Parangi S, Gunda V, Boland GM, Bueno R, Palakurthi S, Freeman GJ, Ritz J, Haining WN, Sharpless NE, Arthanari H, Shapiro GI, Barbie DA, Gray NS, Wong KK.

Cancer Discov. 2018 Feb;8(2):216-233. doi: 10.1158/2159-8290.CD-17-0915. Epub 2017 Nov 3.

PMID:
29101163
15.

Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.

Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, Wei Z, Palakurthi S, Bittinger M, Vitzthum H, Kim JW, Merlino A, Quinn M, Venkataramani C, Kaplan JA, Portell A, Gokhale PC, Phillips B, Smart A, Rotem A, Jones RE, Keogh L, Anguiano M, Stapleton L, Jia Z, Barzily-Rokni M, Cañadas I, Thai TC, Hammond MR, Vlahos R, Wang ES, Zhang H, Li S, Hanna GJ, Huang W, Hoang MP, Piris A, Eliane JP, Stemmer-Rachamimov AO, Cameron L, Su MJ, Shah P, Izar B, Thakuria M, LeBoeuf NR, Rabinowits G, Gunda V, Parangi S, Cleary JM, Miller BC, Kitajima S, Thummalapalli R, Miao B, Barbie TU, Sivathanu V, Wong J, Richards WG, Bueno R, Yoon CH, Miret J, Herlyn M, Garraway LA, Van Allen EM, Freeman GJ, Kirschmeier PT, Lorch JH, Ott PA, Hodi FS, Flaherty KT, Kamm RD, Boland GM, Wong KK, Dornan D, Paweletz CP, Barbie DA.

Cancer Discov. 2018 Feb;8(2):196-215. doi: 10.1158/2159-8290.CD-17-0833. Epub 2017 Nov 3.

PMID:
29101162
16.

Sexual health and students: the pathways travelled by those with sexual health concerns.

Freeman G, Smith LW, McNulty A, Donovan B.

Sex Health. 2018 Feb;15(1):76-78. doi: 10.1071/SH17083.

PMID:
29050552
17.

Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer.

Masugi Y, Nishihara R, Hamada T, Song M, da Silva A, Kosumi K, Gu M, Shi Y, Li W, Liu L, Nevo D, Inamura K, Cao Y, Liao X, Nosho K, Chan AT, Giannakis M, Bass AJ, Hodi FS, Freeman GJ, Rodig SJ, Fuchs CS, Qian ZR, Nowak JA, Ogino S.

Cancer Immunol Res. 2017 Nov;5(11):1046-1055. doi: 10.1158/2326-6066.CIR-17-0122. Epub 2017 Oct 16.

PMID:
29038297
18.

Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.

Speranza MC, Passaro C, Ricklefs F, Kasai K, Klein SR, Nakashima H, Kaufmann JK, Ahmed AK, Nowicki MO, Obi P, Bronisz A, Aguilar-Cordova E, Aguilar LK, Guzik BW, Breakefield X, Weissleder R, Freeman GJ, Reardon DA, Wen PY, Chiocca EA, Lawler SE.

Neuro Oncol. 2018 Jan 22;20(2):225-235. doi: 10.1093/neuonc/nox139.

PMID:
29016938
19.

PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer.

Kansy BA, Concha-Benavente F, Srivastava RM, Jie HB, Shayan G, Lei Y, Moskovitz J, Moy J, Li J, Brandau S, Lang S, Schmitt NC, Freeman GJ, Gooding WE, Clump DA, Ferris RL.

Cancer Res. 2017 Nov 15;77(22):6353-6364. doi: 10.1158/0008-5472.CAN-16-3167. Epub 2017 Sep 13.

PMID:
28904066
20.

Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy.

Zhang Y, Kurupati R, Liu L, Zhou XY, Zhang G, Hudaihed A, Filisio F, Giles-Davis W, Xu X, Karakousis GC, Schuchter LM, Xu W, Amaravadi R, Xiao M, Sadek N, Krepler C, Herlyn M, Freeman GJ, Rabinowitz JD, Ertl HCJ.

Cancer Cell. 2017 Sep 11;32(3):377-391.e9. doi: 10.1016/j.ccell.2017.08.004.

PMID:
28898698
21.

Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.

Carey CD, Gusenleitner D, Lipschitz M, Roemer MGM, Stack EC, Gjini E, Hu X, Redd R, Freeman GJ, Neuberg D, Hodi FS, Liu XS, Shipp MA, Rodig SJ.

Blood. 2017 Nov 30;130(22):2420-2430. doi: 10.1182/blood-2017-03-770719. Epub 2017 Sep 11.

PMID:
28893733
22.

Extracellular Vesicles Transfer the Receptor Programmed Death-1 in Rheumatoid Arthritis.

Greisen SR, Yan Y, Hansen AS, Venø MT, Nyengaard JR, Moestrup SK, Hvid M, Freeman GJ, Kjems J, Deleuran B.

Front Immunol. 2017 Jul 24;8:851. doi: 10.3389/fimmu.2017.00851. eCollection 2017.

23.

Effect of Early and Prophylactic Nonsteroidal Anti-Inflammatory Drugs on Flare Duration in Pediatric Acute-Onset Neuropsychiatric Syndrome: An Observational Study of Patients Followed by an Academic Community-Based Pediatric Acute-Onset Neuropsychiatric Syndrome Clinic.

Brown KD, Farmer C, Freeman GM Jr, Spartz EJ, Farhadian B, Thienemann M, Frankovich J.

J Child Adolesc Psychopharmacol. 2017 Sep;27(7):619-628. doi: 10.1089/cap.2016.0193. Epub 2017 Jul 11.

PMID:
28696786
24.

Course of Neuropsychiatric Symptoms After Introduction and Removal of Nonsteroidal Anti-Inflammatory Drugs: A Pediatric Observational Study.

Spartz EJ, Freeman GM Jr, Brown K, Farhadian B, Thienemann M, Frankovich J.

J Child Adolesc Psychopharmacol. 2017 Sep;27(7):652-659. doi: 10.1089/cap.2016.0179. Epub 2017 Jul 11.

PMID:
28696783
25.

Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition.

Gil Del Alcazar CR, Huh SJ, Ekram MB, Trinh A, Liu LL, Beca F, Zi X, Kwak M, Bergholtz H, Su Y, Ding L, Russnes HG, Richardson AL, Babski K, Min Hui Kim E, McDonnell CH 3rd, Wagner J, Rowberry R, Freeman GJ, Dillon D, Sorlie T, Coussens LM, Garber JE, Fan R, Bobolis K, Allred DC, Jeong J, Park SY, Michor F, Polyak K.

Cancer Discov. 2017 Oct;7(10):1098-1115. doi: 10.1158/2159-8290.CD-17-0222. Epub 2017 Jun 26.

PMID:
28652380
26.

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016.

Adusumilli PS, Cha E, Cornfeld M, Davis T, Diab A, Dubensky TW Jr, Evans E, Grogan JL, Irving BA, Leidner RS, Olwill SA, Soon-Shiong P, Triebel F, Tuck D, Bot A, Dansey RD, Drake CG, Freeman GJ, Ibrahim R, Patel S, Chen DS.

J Immunother Cancer. 2017 Jun 20;5:50. doi: 10.1186/s40425-017-0253-2. eCollection 2017. Review.

27.

Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.

Zhou J, Mahoney KM, Giobbie-Hurder A, Zhao F, Lee S, Liao X, Rodig S, Li J, Wu X, Butterfield LH, Piesche M, Manos MP, Eastman LM, Dranoff G, Freeman GJ, Hodi FS.

Cancer Immunol Res. 2017 Jun;5(6):480-492. doi: 10.1158/2326-6066.CIR-16-0329. Epub 2017 May 18.

28.

Labeling Extracellular Vesicles for Nanoscale Flow Cytometry.

Morales-Kastresana A, Telford B, Musich TA, McKinnon K, Clayborne C, Braig Z, Rosner A, Demberg T, Watson DC, Karpova TS, Freeman GJ, DeKruyff RH, Pavlakis GN, Terabe M, Robert-Guroff M, Berzofsky JA, Jones JC.

Sci Rep. 2017 May 12;7(1):1878. doi: 10.1038/s41598-017-01731-2.

29.

In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy.

Arlauckas SP, Garris CS, Kohler RH, Kitaoka M, Cuccarese MF, Yang KS, Miller MA, Carlson JC, Freeman GJ, Anthony RM, Weissleder R, Pittet MJ.

Sci Transl Med. 2017 May 10;9(389). pii: eaal3604. doi: 10.1126/scitranslmed.aal3604.

30.

Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.

Wankowicz SAM, Werner L, Orsola A, Novak J, Bowden M, Choueiri TK, de Torres I, Morote J, Freeman GJ, Signoretti S, Bellmunt J.

J Urol. 2017 Oct;198(4):817-823. doi: 10.1016/j.juro.2017.04.102. Epub 2017 May 6.

PMID:
28487100
31.

Interleukin-17A Promotes Lung Tumor Progression through Neutrophil Attraction to Tumor Sites and Mediating Resistance to PD-1 Blockade.

Akbay EA, Koyama S, Liu Y, Dries R, Bufe LE, Silkes M, Alam MM, Magee DM, Jones R, Jinushi M, Kulkarni M, Carretero J, Wang X, Warner-Hatten T, Cavanaugh JD, Osa A, Kumanogoh A, Freeman GJ, Awad MM, Christiani DC, Bueno R, Hammerman PS, Dranoff G, Wong KK.

J Thorac Oncol. 2017 Aug;12(8):1268-1279. doi: 10.1016/j.jtho.2017.04.017. Epub 2017 May 6.

32.

Chemical and biological assessment of metal organic frameworks (MOFs) in pulmonary cells and in an acute in vivo model: relevance to pulmonary arterial hypertension therapy.

Mohamed NA, Davies RP, Lickiss PD, Ahmetaj-Shala B, Reed DM, Gashaw HH, Saleem H, Freeman GR, George PM, Wort SJ, Morales-Cano D, Barreira B, Tetley TD, Chester AH, Yacoub MH, Kirkby NS, Moreno L, Mitchell JA.

Pulm Circ. 2017 Jul-Sep;7(3):643-653. doi: 10.1177/2045893217710224. Epub 2017 Jun 27.

33.

Expression of lectin-like transcript-1 in human tissues.

Llibre A, Garner L, Partridge A, Freeman GJ, Klenerman P, Willberg CB.

F1000Res. 2016 Dec 29;5:2929. doi: 10.12688/f1000research.10009.1. eCollection 2016.

34.

Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status.

Hamada T, Cao Y, Qian ZR, Masugi Y, Nowak JA, Yang J, Song M, Mima K, Kosumi K, Liu L, Shi Y, da Silva A, Gu M, Li W, Keum N, Zhang X, Wu K, Meyerhardt JA, Giovannucci EL, Giannakis M, Rodig SJ, Freeman GJ, Nevo D, Wang M, Chan AT, Fuchs CS, Nishihara R, Ogino S.

J Clin Oncol. 2017 Jun 1;35(16):1836-1844. doi: 10.1200/JCO.2016.70.7547. Epub 2017 Apr 13.

35.

PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity.

Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Haining WN, Freeman GJ, Sharpe AH.

J Exp Med. 2017 Apr 3;214(4):895-904. doi: 10.1084/jem.20160801. Epub 2017 Mar 16.

36.

Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.

Kamphorst AO, Wieland A, Nasti T, Yang S, Zhang R, Barber DL, Konieczny BT, Daugherty CZ, Koenig L, Yu K, Sica GL, Sharpe AH, Freeman GJ, Blazar BR, Turka LA, Owonikoko TK, Pillai RN, Ramalingam SS, Araki K, Ahmed R.

Science. 2017 Mar 31;355(6332):1423-1427. doi: 10.1126/science.aaf0683. Epub 2017 Mar 9.

37.

Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.

George S, Miao D, Demetri GD, Adeegbe D, Rodig SJ, Shukla S, Lipschitz M, Amin-Mansour A, Raut CP, Carter SL, Hammerman P, Freeman GJ, Wu CJ, Ott PA, Wong KK, Van Allen EM.

Immunity. 2017 Feb 21;46(2):197-204. doi: 10.1016/j.immuni.2017.02.001.

38.
39.

Proceedings of the third international molecular pathological epidemiology (MPE) meeting.

Campbell PT, Rebbeck TR, Nishihara R, Beck AH, Begg CB, Bogdanov AA, Cao Y, Coleman HG, Freeman GJ, Heng YJ, Huttenhower C, Irizarry RA, Kip NS, Michor F, Nevo D, Peters U, Phipps AI, Poole EM, Qian ZR, Quackenbush J, Robins H, Rogan PK, Slattery ML, Smith-Warner SA, Song M, VanderWeele TJ, Xia D, Zabor EC, Zhang X, Wang M, Ogino S.

Cancer Causes Control. 2017 Feb;28(2):167-176. doi: 10.1007/s10552-016-0845-z. Epub 2017 Jan 17. Review.

40.

5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.

Van Der Kraak L, Goel G, Ramanan K, Kaltenmeier C, Zhang L, Normolle DP, Freeman GJ, Tang D, Nason KS, Davison JM, Luketich JD, Dhupar R, Lotze MT.

J Immunother Cancer. 2016 Oct 18;4:65. doi: 10.1186/s40425-016-0163-8. eCollection 2016.

41.

Type 2 innate lymphoid cell suppression by regulatory T cells attenuates airway hyperreactivity and requires inducible T-cell costimulator-inducible T-cell costimulator ligand interaction.

Rigas D, Lewis G, Aron JL, Wang B, Banie H, Sankaranarayanan I, Galle-Treger L, Maazi H, Lo R, Freeman GJ, Sharpe AH, Soroosh P, Akbari O.

J Allergy Clin Immunol. 2017 May;139(5):1468-1477.e2. doi: 10.1016/j.jaci.2016.08.034. Epub 2016 Oct 4.

42.

Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer.

Herter-Sprie GS, Koyama S, Korideck H, Hai J, Deng J, Li YY, Buczkowski KA, Grant AK, Ullas S, Rhee K, Cavanaugh JD, Neupane NP, Christensen CL, Herter JM, Makrigiorgos GM, Hodi FS, Freeman GJ, Dranoff G, Hammerman PS, Kimmelman AC, Wong KK.

JCI Insight. 2016 Jun 16;1(9):e87415.

43.

Increased expression of programmed death ligand 1 (PD-L1) in human pituitary tumors.

Mei Y, Bi WL, Greenwald NF, Du Z, Agar NY, Kaiser UB, Woodmansee WW, Reardon DA, Freeman GJ, Fecci PE, Laws ER Jr, Santagata S, Dunn GP, Dunn IF.

Oncotarget. 2016 Nov 22;7(47):76565-76576. doi: 10.18632/oncotarget.12088.

44.

Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.

Im SJ, Hashimoto M, Gerner MY, Lee J, Kissick HT, Burger MC, Shan Q, Hale JS, Lee J, Nasti TH, Sharpe AH, Freeman GJ, Germain RN, Nakaya HI, Xue HH, Ahmed R.

Nature. 2016 Sep 15;537(7620):417-421. doi: 10.1038/nature19330. Epub 2016 Aug 2.

45.

In vivo assessment of behavioral recovery and circulatory exchange in the peritoneal parabiosis model.

Castellano JM, Palner M, Li SB, Freeman GM Jr, Nguyen A, Shen B, Stan T, Mosher KI, Chin FT, de Lecea L, Luo J, Wyss-Coray T.

Sci Rep. 2016 Jul 1;6:29015. doi: 10.1038/srep29015.

46.

Health of Hispanic Adults: United States, 2010-2014.

Lucas JW, Freeman G, Adams PF.

NCHS Data Brief. 2016 Jun;(251):1-8.

47.

Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes.

Sridharan V, Gjini E, Liao X, Chau NG, Haddad RI, Severgnini M, Hammerman P, El-Naggar A, Freeman GJ, Hodi FS, Rodig SJ, Dranoff G, Schoenfeld JD.

Cancer Immunol Res. 2016 Aug;4(8):679-87. doi: 10.1158/2326-6066.CIR-16-0031. Epub 2016 Jun 16.

48.

Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality.

Saha A, O'Connor RS, Thangavelu G, Lovitch SB, Dandamudi DB, Wilson CB, Vincent BG, Tkachev V, Pawlicki JM, Furlan SN, Kean LS, Aoyama K, Taylor PA, Panoskaltsis-Mortari A, Foncea R, Ranganathan P, Devine SM, Burrill JS, Guo L, Sacristan C, Snyder NW, Blair IA, Milone MC, Dustin ML, Riley JL, Bernlohr DA, Murphy WJ, Fife BT, Munn DH, Miller JS, Serody JS, Freeman GJ, Sharpe AH, Turka LA, Blazar BR.

J Clin Invest. 2016 Jul 1;126(7):2642-60. doi: 10.1172/JCI85796. Epub 2016 Jun 13.

49.

Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma.

Mullane SA, Werner L, Rosenberg J, Signoretti S, Callea M, Choueiri TK, Freeman GJ, Bellmunt J.

Sci Rep. 2016 Jun 10;6:27702. doi: 10.1038/srep27702.

50.

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.

Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, Dhodapkar M, Avigan D, Chapuy B, Ligon AH, Freeman GJ, Rodig SJ, Cattry D, Zhu L, Grosso JF, Bradley Garelik MB, Shipp MA, Borrello I, Timmerman J.

J Clin Oncol. 2016 Aug 10;34(23):2698-704. doi: 10.1200/JCO.2015.65.9789. Epub 2016 Jun 6.

Supplemental Content

Loading ...
Support Center